JPMorgan Chase & Co. reissued their overweight rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Friday, February 2nd. The brokerage currently has a GBX 5,500 ($75.99) price target on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently weighed in on AZN. Barclays reiterated an overweight rating and issued a GBX 6,300 ($87.04) price target on shares of AstraZeneca in a report on Thursday, October 5th. Deutsche Bank reiterated a buy rating and issued a GBX 5,600 ($77.37) price target on shares of AstraZeneca in a report on Thursday, October 5th. upped their price objective on AstraZeneca from GBX 4,100 ($56.65) to GBX 4,150 ($57.34) and gave the stock a reduce rating in a research note on Monday, October 9th. Shore Capital restated a hold rating on shares of AstraZeneca in a research note on Monday, October 9th. Finally, UBS Group set a GBX 4,550 ($62.86) price objective on AstraZeneca and gave the stock a neutral rating in a research note on Monday, October 9th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of GBX 5,211.65 ($72.00).
AstraZeneca (LON:AZN) opened at GBX 4,860 ($67.15) on Friday. AstraZeneca has a 52-week low of GBX 4,260 ($58.86) and a 52-week high of GBX 5,520 ($76.26). The stock has a market capitalization of $61,540.00 and a P/E ratio of 2,858.82.
The company also recently announced a dividend, which will be paid on Monday, March 19th. Shareholders of record on Thursday, February 15th will be given a GBX 133.60 ($1.85) dividend. This is a positive change from AstraZeneca’s previous dividend of $68.90. This represents a yield of 2.8%. The ex-dividend date of this dividend is Thursday, February 15th.
In other news, insider Philip A. J. Broadley bought 415 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were bought at an average cost of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/13/astrazeneca-azn-given-a-gbx-5500-price-target-by-jpmorgan-chase-co-analysts-2.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.